Review
Medicine, General & Internal
Quirino Lai, Gianluca Mennini, Francesco Giovanardi, Massimo Rossi, Edoardo G. Giannini
Summary: Prophylaxis with HBIG is effective in preventing post-LT HBV recurrence, and its combination with NUC provides the best protection. Further studies on high genetic barrier-to-recurrence NUC and protocols with definitive use of HBIG are needed to optimize prophylactic strategies.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
(2021)
Article
Gastroenterology & Hepatology
Li-Ping Sheng, Jun-Chang Zhang, Zhi-Qiang Zhong, Xue-Han Sheng, Jing Ren, Gui-Qiang Wang
Summary: The optimal prophylactic regimen for preventing hepatitis B virus (HBV) recurrence after liver transplantation (LT) in HBV-infected patients is uncertain. New evidence suggests that an HBIG-free approach may be feasible when combined with high-potency nucleos(t)ide analogues (HPNAs). This study provides robust estimates for long-term survival and HBV recurrence in patients receiving different HBV-prophylaxis strategies after LT.
HEPATOLOGY INTERNATIONAL
(2023)
Article
Gastroenterology & Hepatology
Yan Xue, Meng Zhang, Tao Li, Feng Liu, Li-Xin Zhang, Xiao-Ping Fan, Bao-Hua Yang, Lei Wang
Summary: In HBeAg-positive CHB patients with HBeAg loss, the consolidation period and HBsAg level at cessation were significant predictors of virological relapse after discontinuation of NAs. Patients with HBeAg seroconversion had lower cumulative relapse rates. Careful monitoring, especially in the early stages after cessation, may lead to a favorable outcome.
WORLD JOURNAL OF GASTROENTEROLOGY
(2021)
Review
Public, Environmental & Occupational Health
Mian Wang, Mingxia Qian, Rongrong Fu, Yiqin Zhang, Xinlan Shen, Dengyuan Yue, Ning Wang, Lei Yang
Summary: This study compared the long-term outcomes between CHB patients who discontinued nucleos(t)ide analogs therapy and those who continued it, revealing that off-therapy patients had a higher risk of ALT flares-up and virological abnormalities. However, there were no significant differences in hyperbilirubinemia, hepatic decompensation, and HCC development between the two groups.
FRONTIERS IN PUBLIC HEALTH
(2021)
Article
Medicine, General & Internal
Yachao Tao, Menglan Wang, Juan Liao, Xing Cheng, Min He, Dongmei Zhang, Taoyou Zhou, Jie Chen, Enqiang Chen, Hong Tang
Summary: This study found that serum pgRNA levels were strongly correlated with HBV DNA and HBsAg levels. Low levels of serum pgRNA before treatment may indicate a high probability of HBeAg seroconversion. The baseline serum pgRNA level could serve as a novel predictor for HBeAg seroconversion.
FRONTIERS IN MEDICINE
(2022)
Article
Virology
Shun Kaneko, Masayuki Kurosaki, Toshie Mashiba, Hiroyuki Marusawa, Masahiko Kondo, Yuji Kojima, Yasushi Uchida, Hideki Fujii, Takehiro Akahane, Hitoshi Yagisawa, Atsunori Kusakabe, Haruhiko Kobashi, Takehiko Abe, Hideo Yoshida, Chikara Ogawa, Koichiro Furuta, Nobuharu Tamaki, Keiji Tsuji, Tomomichi Matsushita, Namiki Izumi
Summary: This study aimed to identify the risk factors for HCC development in naive CHB patients treated with current NA. Age, cirrhosis, baseline platelet counts, ALBI score, and AFP one year after NA therapy were found to be independent predictive factors for HCC development. The aMAP and REAL-B scores demonstrated high accuracy in predicting HCC development.
JOURNAL OF MEDICAL VIROLOGY
(2023)
Article
Medicine, Research & Experimental
Hong Shi, Gemin Xiao, Mei Liao, Lihua Zheng, Yusheng Jie, Guoli Lin, Yutian Chong
Summary: Inappropriate cessation of nucleos(t)ide analog therapy is associated with poor prognosis in patients with HBV-related ACLF, with lower short-term and long-term survival rates in patients using NAs and higher risk for liver transplantation.
BIOMEDICINE & PHARMACOTHERAPY
(2021)
Article
Biochemistry & Molecular Biology
Jyun-Yi Wu, Yi-Shan Tsai, Chia-Chen Li, Ming-Lun Yeh, Ching- Huang, Chung-Feng Huang, Jia-Ning Hsu, Meng-Hsuan Hsieh, Yo-Chia Chen, Ta-Wei Liu, Yi-Hung Lin, Po-Cheng Liang, Zu-Yau Lin, Wan-Long Chuang, Ming-Lung Yu, Chia-Yen Dai
Summary: This study aimed to investigate the association between serum miR-125b and liver fibrosis progression in chronic hepatitis B (CHB) patients after nucleos(t)ide analog (NA) treatment. The results showed that baseline miR-125b levels were inversely correlated with the post-treatment FIB-4 index. Age, baseline platelet level, and ALT level were identified as independent predictors of higher FIB-index after 12-month treatment. In patients receiving entecavir (ETV) monotherapy, the alteration of serum miR-125b and age were significantly associated with higher post-treatment FIB-4 index.
Article
Gastroenterology & Hepatology
Jose-Manuel Ramos-Rincon, Hector Pinargote-Celorio, Carmen de Mendoza, Clara Ramos-Belinchon, Pablo Barreiro, Ana Trevino, Octavio Corral, Vicente Soriano
Summary: Hospital admissions of individuals with HBV infection are increasing in Spain, and while hepatic decompensation events have declined, HBV-related liver cancer continues to rise. Oral antiviral therapies do not have any benefit on hepatitis delta.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Gastroenterology & Hepatology
Wen-Xiong Xu, Yang-Mei Li, Jian-Guo Li, Yong-Yu Mei, You-Ming Chen, Xue-Jun Li, Chao-Shuang Lin, Hong Deng, Zhi-Xin Zhao, Dong-Ying Xie, Zhi-Liang Gao, Liang Peng
Summary: CHB patients have four types of clinical outcomes after cessation of NA treatment, with different risk factors for relapse that need further exploration. The EOT HBsAg level is independently associated with both virological and clinical relapse.
GASTROENTEROLOGY REPORT
(2021)
Article
Gastroenterology & Hepatology
Jia-Horng Kao, Wen-Juei Jeng, Qin Ning, Tung-Hung Su, Tai-Chung Tseng, Yoshiyuki Ueno, Man-Fung Yuen
Summary: Chronic HBV infection is currently incurable and long-term treatment with NAs can reduce complications, but stopping treatment may lead to virological relapse and adverse outcomes. Close monitoring and personalized follow-up strategies are essential for a safe cessation of NA therapy.
HEPATOLOGY INTERNATIONAL
(2021)
Review
Pharmacology & Pharmacy
Issam Tout, Pietro Lampertico, Thomas Berg, Tarik Asselah
Summary: Long-term treatment with NAs is the current first line therapy for patients with CHB, preventing disease progression and liver failure. However, low rates of on-therapy functional cure hinder many patients from stopping NA therapy, leading to the need for lifelong treatment.
ANTIVIRAL RESEARCH
(2021)
Article
Medicine, General & Internal
Julian Hercun, Theo Heller, Jeffrey S. Glenn, David E. Kleiner, Christopher Koh
Summary: This study evaluates the impact of nucleos(t)ide analogs on the histological appearance of chronic HDV infection and finds that patients on nucleos(t)ide analogs demonstrate a unique membranous staining pattern.
FRONTIERS IN MEDICINE
(2023)
Article
Immunology
Rafael Mican, Alejandro de Gea Grela, Julen Cadinanos, Rosa de Miguel, Carmen Busca, Jose Bernardino, Eulalia Valencia, Maria Luisa Montes, Rocio Montejano, Victoria Moreno, Ignacio Perez Valero, Lucia Serrano, Juan Gonzalez-Garcia, Jose R. Arribas, Luz Martin-Carbonero
Summary: This study retrospectively evaluated the efficacy of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in HIV patients with preexisting NRTI resistance-associated mutations. The results demonstrated that switching to B/F/TAF is well tolerated and effective, even in patients with previous NRTI RAMs such as M184V and tenofovir resistance.
Article
Virology
Hao Liao, He Zhang, Jinman Shao, Xiaoyong Li, Wei V. Zheng, Le Li, Guangxin Yu, Lanlan Si, Tao Zhou, Zengtao Yao, Jiuzeng Dai, Dongping Xu, Guanxun Cheng, Jiuxin Qu, Yan Liu, Junhui Chen, Fengmin Lu
Summary: This study aimed to investigate the dynamic changes of serum hepatitis B virus (HBV) RNA levels and the quasispecies of HBV RNA virus-like particles in nucleos(t)ide analogues (NAs)-experienced chronic hepatitis B patients with NAs-resistant mutations and their effects on NAs resistance. The results showed that serum HBV RNA can reflect virological breakthrough and rebound earlier than HBV DNA in some patients. However, there are limitations in the detection of serum HBV RNA levels and drug-resistant mutations compared to serum HBV DNA.
JOURNAL OF MEDICAL VIROLOGY
(2023)
Article
Gastroenterology & Hepatology
Hannah S. J. Choi, Grishma Hirode, Chien-Hung Chen, Tung-Hung Su, Wai-Kay Seto, Stijn Van Hees, Margarita Papatheodoridi, Sabela Lens, Grace L. H. Wong, Sylvia M. Brakenhoff, Rong-Nan Chien, Jordan J. Feld, Milan J. Sonneveld, Henry L. Y. Chan, Xavier Forns, George Papatheodoridis, Thomas Vanwolleghem, Man-Fung Yuen, Yao-Chun Hsu, Jia-Horn Kao, Markus Cornberg, Bettina E. Hansen, Wen-Jue Jeng, Harry L. A. Janssen
Summary: This study compared the relapse rates and treatment outcomes after discontinuation of therapy in chronic hepatitis B patients using entecavir (ETV) and tenofovir disoproxil fumarate (TDF). It found that TDF was associated with a higher rate of HBsAg loss, earlier virological relapse, and higher clinical relapse compared to ETV. However, the rates of HBsAg loss and retreatment were similar between the two treatment groups. Finite therapy can be considered for CHB patients on either TDF or ETV therapy.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Lung-Yi Mak, Danny Wong, Alison Kuchta, Martina Hilfiker, Aaron Hamilton, Ning Chow, XianHua Mao, Wai Kay Seto, Man-Fung Yuen
Summary: This study investigated the dynamics of serum HBV pre-genomic RNA (pgRNA) and hepatitis B core-related antigen (HBcrAg) in patients receiving nucleos(t)ide analogues (NAs) and their predictability for favourable suppression of serum hepatitis B surface antigen (HBsAg). The results showed that early on-treatment changes of serum HBV pgRNA and HBcrAg at 4 weeks can predict HBsAg seroclearance or <100 IU/mL in NA-treated CHB patients upon long-term follow-up.
CLINICAL AND MOLECULAR HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Yong-Wen Leow, Wah-Kheong Chan, George Boon-Bee Goh, Vincent Wai-Sun Wong, Jian Gao Fan, Young Seok Kim, Seung Up Kim, Atsushi Nakajima, Wai-Kay Seto, I-Cheng Lee, Yi-Hsiang Huang, Yoon Jun Kim, Jang Jae Young, Wan Cheng Chow
Summary: We conducted a clinical study on patients with chronic hepatitis B (CHB) to compare the severity, metabolic profile, and cardiovascular disease (CVD) risk of patients with and without hepatic steatosis, as well as patients with non-alcoholic fatty liver disease (NAFLD). The study found that a high proportion (59%) of CHB patients had hepatic steatosis. There was a gradual increase in liver function indicators, liver stiffness measurement, metabolic syndrome prevalence, and CVD risk from CHB patients without hepatic steatosis to CHB patients with hepatic steatosis to NAFLD patients. Therefore, CHB patients with hepatic steatosis should be diagnosed and managed according to their metabolic risk factors for better long-term outcomes.
JOURNAL OF VIRAL HEPATITIS
(2023)
Letter
Gastroenterology & Hepatology
Lung-Yi Mak, Wai-Kay Seto, Man-Fung Yuen
CLINICAL AND MOLECULAR HEPATOLOGY
(2023)
Review
Pharmacology & Pharmacy
Lung-Yi Mak, Rex Wan-Hin Hui, Ka-Shing Cheung, James Fung, Wai-Kay Seto, Man-Fung Yuen
Summary: Chronic hepatitis B (CHB) infection is a significant global health threat, and understanding the interaction between hepatitis B virus (HBV) and the host immune system can lead to the discovery of new biomarkers and treatment options. Viral biomarkers such as HBsAg, HBV RNA, and hepatitis B core-related antigen can help select patients who can benefit from antiviral therapy cessation and assess treatment efficacy. Novel viral and immunological biomarkers play a crucial role in the HBV functional cure program and may soon become a standard monitoring tool.
EXPERT OPINION ON DRUG DISCOVERY
(2023)
Article
Gastroenterology & Hepatology
Tao Lyu, Ka Shing Cheung, Zijie Deng, Li Ni, Chuan Chen, Juan Wu, Wai K. Leung, Wai Kay Seto
Summary: Whole genome sequencing of Helicobacter pylori revealed potential novel genetic mutations associated with clarithromycin and levofloxacin resistance, including fliJ and cheA genes, which may improve predictive accuracy for targeted sequencing tests in the future.
Article
Virology
Danny Ka-Ho Wong, Takako Inoue, Lung-Yi Mak, Rex Wan-Hin Hui, James Fung, Ka-Shing Cheung, Wai-Kay Seto, Yasuhito Tanaka, Man-Fung Yuen
Summary: This study evaluated the usefulness of two novel assays, the iTACT-HBsAg and iTACT-HBcrAg assays, in CHB patients with HBsAg seroclearance (SC). The results showed that over 70% of patients still had a low level of HBV protein expression even at 10 years after SC, indicating that CHB patients with SC still harbor a low level of HBV. Further investigations are needed to determine the clinical significance of detectable viral proteins after SC.
JOURNAL OF CLINICAL VIROLOGY
(2023)
Review
Gastroenterology & Hepatology
Rex Wan-Hin Hui, Lung-Yi Mak, Wai-Kay Seto, Man-Fung Yuen, James Fung
Summary: Nucleos(t)ide analogues (NAs) effectively suppress the replication of hepatitis B virus, but do not effectively induce the clearance of hepatitis B surface antigen (HBsAg), which is the optimal treatment endpoint in chronic hepatitis B (CHB). Recent studies have supported the concept of finite NA therapy before HBsAg seroclearance.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY
(2023)
Letter
Gastroenterology & Hepatology
Sebastian Staubli, Alexander Steen Grover, Benedict R. H. Turner, Dimitri A. Raptis, Michael Spiro, Marina Berenguer, Pascale Tinguely, LDL Tregistry Org Collaborative
LANCET GASTROENTEROLOGY & HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Karin Kan, Danny Ka-Ho Wong, Rex Wan-Hin Hui, Wai Kay Seto, Man-Fung Yuen, Lung-Yi Mak
Summary: Low plasma levels of IP-10 are associated with subsequent HBsAg seroclearance, suggesting potential clinical utilities of measurement of IP-10 in predicting HBsAg seroclearance, especially among patients with low HBsAg.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Virology
Lok-Ka Lam, Thomas Sau Yan Chan, Yu-Yan Hwang, Lung-Yi Mak, Wai-Kay Seto, Yok-Lam Kwong, Man-Fung Yuen
Summary: This case report describes the reactivation of hepatitis B virus in a patient undergoing ibrutinib treatment. The authors emphasize the importance of systematic screening for hepatitis B exposure prior to ibrutinib treatment and subsequent monitoring of serological and molecular markers of hepatitis B.
Article
Gastroenterology & Hepatology
Young-Suk Lim, Henry L. Y. Chan, Sang Hoon Ahn, Wai Kay Seto, Qin Ning, Kosh Agarwal, Harry L. A. Janssen, Calvin Q. Pan, Wan Long Chuang, Namiki Izumi, Scott Fung, Maurizia Shalimar, Maurizia Brunetto, Aric Josun Hui, Ting-Tsung Chang, Seng Gee Lim, Frida Abramov, John F. Flaherty, Hongyuan Wang, Leland J. Yee, Jia-Horng Kao, Edward Gane, Jinlin Hou, Maria Buti
Summary: This study evaluated the impact of tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF) on the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). The study found that patients receiving TAF treatment had a lower risk of HCC compared to those receiving TDF treatment, especially in patients without cirrhosis.
Meeting Abstract
Gastroenterology & Hepatology
Xinxiang Yang, Jinyang Li, Rongrong Zhong, Rui Shen, Jiaqi Wang, Congwen Bian, Kevin Tak-Pan Ng, Kwan Man
Review
Gastroenterology & Hepatology
Joerg M. Pollok, Pascale Tinguely, Marina Berenguer, Claus U. Niemann, Dimitri A. Raptis, Michael Spiro
Summary: There is significant controversy surrounding enhanced recovery for liver-transplant recipients, and this review aimed to summarize current knowledge, identify key components, and create internationally accepted guidelines. A collaborative effort by the ERAS4OLT.org partnership and specialists from around the world resulted in 80 final recommendations covering various aspects of enhanced recovery for liver transplantation. These guidelines provide a comprehensive overview and can guide the development of enhanced recovery programs globally.
LANCET GASTROENTEROLOGY & HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Fung-Yu Huang, Danny Ka-Ho Wong, Lung-Yi Mak, Tan-To Cheung, Sai-Sai Zhang, Hau-Tak Chau, Rex Wan-Hin Hui, Wai-Kay Seto, Man-Fung Yuen
Summary: Our study reveals that the loss of FAT4 drives HCC development by switching canonical signaling pathways to noncanonical pathways, and this transformation process involves the regulation of multiple molecules and signaling pathways.
HEPATOLOGY COMMUNICATIONS
(2023)